This application seeks renewed CCSG funding for the University of Virginia (UVA) Cancer Center, a matrix cancer center that brings together 132 Members from 26 Departments in the Schools of Medicine, Nursing, and Engineering, and in the College of Arts and Sciences. The UVA Cancer Center receives $25.96M from NCI, $32.65M from other peer-reviewed sources, and $4.36M from non-peer-reviewed sources, for a total of $62.97M in overall funding. Through faculty recruitment and robust infrastructure development, the UVA Cancer Center has continued to build on its exceptional basic science foundations and has greatly enhanced its ability to accelerate clinical and translational cancer focused research. Since the last renewal, over 50 new faculty have been recruited, including twenty-four clinical investigators and/or physician-scientists and twenty- six laboratory scientists, bioengineers, population, and computational biologists. The Cancer Center has five Programs: Chemical and Structural Biology (CSB), Molecular Genetics and Epigenetics (GEN), Cancer Cell Signaling (SIG), Immunology/Immunotherapy (IMM), and Women's Oncology (WON). This application requests support for seven Shared Resources: Advanced Microscopy Facility (AMF), Animal Models of Disease Core (AMDC), Biomolecular Analysis Facility (BAF), Bioinformatics Core (BIC), Biorepository and Tissue Research Facility (BTRF), Biostatistics Shared Resource (BSR), and Flow Cytometry Core (FCC). In addition, we request support for Clinical Protocol and Data Management (CPDM) infrastructure and a Protocol Review and Monitoring System (PRMS). A completely transformed infrastructure for translational and clinical research facilitates investigations using human tissues and the implementation of clinical trials. Substantial new initiatives have been launched to reach underserved populations in Appalachia. This renewal application describes continued outstanding basic cancer research, enhanced cancer focus, and greatly strengthened clinical research leadership and infrastructure.

Public Health Relevance

The UVA Cancer Center's dual mission is to eliminate the threat of cancer, with skilled, compassionate care for the patients of today and with research and education for the patients of the future. Cancer Center Members draw on the deep resources of the University of Virginia to identify, analyze, and validate some of the most significant targets for cancer therapy, diagnosis and prevention, and to speed their translation to clinical application.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
2P30CA044579-26
Application #
9209261
Study Section
Special Emphasis Panel (NCI (E3)-A)
Program Officer
Marino, Michael A
Project Start
1997-09-16
Project End
2022-01-31
Budget Start
2017-02-01
Budget End
2018-01-31
Support Year
26
Fiscal Year
2017
Total Cost
$2,149,473
Indirect Cost
$789,047
Name
University of Virginia
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
065391526
City
Charlottesville
State
VA
Country
United States
Zip Code
22904
Knapp, Kiley A; Pires, Eusebio S; Adair, Sara J et al. (2018) Evaluation of SAS1B as a target for antibody-drug conjugate therapy in the treatment of pancreatic cancer. Oncotarget 9:8972-8984
Kedzierska, Katarzyna Z; Gerber, Livia; Cagnazzi, Daniele et al. (2018) SONiCS: PCR stutter noise correction in genome-scale microsatellites. Bioinformatics 34:4115-4117
Zhang, Xuewei; Kitatani, Kazuyuki; Toyoshima, Masafumi et al. (2018) Ceramide Nanoliposomes as a MLKL-Dependent, Necroptosis-Inducing, Chemotherapeutic Reagent in Ovarian Cancer. Mol Cancer Ther 17:50-59
Cruickshanks, Nichola; Zhang, Ying; Hine, Sarah et al. (2018) Discovery and Therapeutic Exploitation of Mechanisms of Resistance to MET Inhibitors in Glioblastoma. Clin Cancer Res :
Balogh, Kristen N; Templeton, Dennis J; Cross, Janet V (2018) Macrophage Migration Inhibitory Factor protects cancer cells from immunogenic cell death and impairs anti-tumor immune responses. PLoS One 13:e0197702
Gonzalez, Phillippe P; Kim, Jungeun; Galvao, Rui Pedro et al. (2018) p53 and NF 1 loss plays distinct but complementary roles in glioma initiation and progression. Glia 66:999-1015
Rodriguez, Anthony B; Peske, J David; Engelhard, Victor H (2018) Identification and Characterization of Tertiary Lymphoid Structures in Murine Melanoma. Methods Mol Biol 1845:241-257
Stowman, Anne M; Hickman, Alexandra W; Mauldin, Ileana S et al. (2018) Lymphoid aggregates in desmoplastic melanoma have features of tertiary lymphoid structures. Melanoma Res 28:237-245
Melhuish, Tiffany A; Kowalczyk, Izabela; Manukyan, Arkadi et al. (2018) Myt1 and Myt1l transcription factors limit proliferation in GBM cells by repressing YAP1 expression. Biochim Biophys Acta Gene Regul Mech 1861:983-995
Kulling, Paige M; Olson, Kristine C; Olson, Thomas L et al. (2018) Calcitriol-mediated reduction in IFN-? output in T cell large granular lymphocytic leukemia requires vitamin D receptor upregulation. J Steroid Biochem Mol Biol 177:140-148

Showing the most recent 10 out of 539 publications